JP2018514568A5 - - Google Patents

Download PDF

Info

Publication number
JP2018514568A5
JP2018514568A5 JP2017556988A JP2017556988A JP2018514568A5 JP 2018514568 A5 JP2018514568 A5 JP 2018514568A5 JP 2017556988 A JP2017556988 A JP 2017556988A JP 2017556988 A JP2017556988 A JP 2017556988A JP 2018514568 A5 JP2018514568 A5 JP 2018514568A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
carbon atom
fibrosis
attached
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2017556988A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018514568A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/029962 external-priority patent/WO2016176532A1/en
Publication of JP2018514568A publication Critical patent/JP2018514568A/ja
Publication of JP2018514568A5 publication Critical patent/JP2018514568A5/ja
Withdrawn legal-status Critical Current

Links

JP2017556988A 2015-04-30 2016-04-29 テトラヒドロナフチリジニルプロピオン酸誘導体およびその使用法 Withdrawn JP2018514568A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562154894P 2015-04-30 2015-04-30
US62/154,894 2015-04-30
PCT/US2016/029962 WO2016176532A1 (en) 2015-04-30 2016-04-29 Tetrahydronaphthyridinyl propionic acid derivatives and uses thereof

Publications (2)

Publication Number Publication Date
JP2018514568A JP2018514568A (ja) 2018-06-07
JP2018514568A5 true JP2018514568A5 (cg-RX-API-DMAC7.html) 2019-05-30

Family

ID=56027176

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017556988A Withdrawn JP2018514568A (ja) 2015-04-30 2016-04-29 テトラヒドロナフチリジニルプロピオン酸誘導体およびその使用法

Country Status (12)

Country Link
US (1) US9572801B2 (cg-RX-API-DMAC7.html)
EP (1) EP3288555A1 (cg-RX-API-DMAC7.html)
JP (1) JP2018514568A (cg-RX-API-DMAC7.html)
KR (1) KR20170141757A (cg-RX-API-DMAC7.html)
CN (1) CN108040467A (cg-RX-API-DMAC7.html)
AU (1) AU2016255494A1 (cg-RX-API-DMAC7.html)
BR (1) BR112017023432A2 (cg-RX-API-DMAC7.html)
CA (1) CA2983312A1 (cg-RX-API-DMAC7.html)
IL (1) IL255054A0 (cg-RX-API-DMAC7.html)
MX (1) MX2017013880A (cg-RX-API-DMAC7.html)
RU (1) RU2017141561A (cg-RX-API-DMAC7.html)
WO (1) WO2016176532A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8901144B2 (en) * 2013-02-07 2014-12-02 Scifluor Life Sciences, Llc Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives
SMT201700611T1 (it) 2013-02-07 2018-01-11 Scifluor Life Sciences Inc Antagonisti fluorurati di integrine
WO2016134223A2 (en) 2015-02-19 2016-08-25 Scifluor Life Sciences, Inc. Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof
US10118929B2 (en) 2016-04-27 2018-11-06 Scifluor Life Sciences, Inc. Nonanoic and decanoic acid derivatives and uses thereof
KR102605460B1 (ko) 2017-02-28 2023-11-22 모픽 테라퓨틱, 인코포레이티드 αvβ6 인테그린 억제제
MA52117A (fr) 2017-02-28 2022-04-06 Morphic Therapeutic Inc Inhibiteurs de l'intégrine (alpha-v) (bêta-6)
JP7704529B2 (ja) * 2018-04-27 2025-07-08 アローヘッド ファーマシューティカルズ インコーポレイテッド インテグリン標的化リガンドとその使用
TWI841573B (zh) * 2018-06-27 2024-05-11 美商普萊恩醫療公司 具有未分支連接子之胺基酸化合物及使用方法
CN112805001B (zh) 2018-08-29 2024-07-23 莫菲克医疗股份有限公司 抑制αvβ6整联蛋白
IL297969A (en) * 2020-05-07 2023-01-01 Pliant Therapeutics Inc Treatment of respiratory diseases with amino acid compounds
JP7585564B2 (ja) * 2020-09-24 2024-11-19 株式会社ファンケル セラミド含有ニオソームを含む化粧料
EP4534083A4 (en) * 2022-05-30 2025-11-19 Scinnohub Pharmaceutical Co Ltd USE OF A TETRAHYDRONAPHTYRIDINE DERIVATIVE FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE PREVENTION AND TREATMENT OF DISEASES RELATED TO ADHESION

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1318254C (en) 1988-01-06 1993-05-25 Munehiro Tomikawa Inhibitory agent of hepatic fibrosis containing pantethine
DE69220050T2 (de) 1991-04-01 1998-01-22 Univ Duke Verfahren zur inhibierung der fibrose
JP3818322B2 (ja) 1994-04-28 2006-09-06 敏一 中村 コラーゲン分解促進剤
US5645839A (en) 1995-06-07 1997-07-08 Trustees Of Boston University Combined use of angiotensin inhibitors and nitric oxide stimulators to treat fibrosis
US6664227B1 (en) 1996-03-01 2003-12-16 Genetics Institute, Llc Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
WO1998008528A1 (en) 1996-08-30 1998-03-05 Biomeasure Incorporated Method of inhibiting fibrosis with a somatostatin agonist
US6017926A (en) 1997-12-17 2000-01-25 Merck & Co., Inc. Integrin receptor antagonists
CN1284955A (zh) * 1997-12-17 2001-02-21 麦克公司 整联蛋白受体拮抗剂
US6117445A (en) 1998-01-28 2000-09-12 Link Technology Inc. Methods for the prevention and treatment of fibrosis and sclerosis
US6500835B2 (en) 2000-02-22 2002-12-31 Suntory Limited Preventive or therapeutic drugs for fibrosis containing chymase inhibitors as the active ingredient
CA2421652A1 (en) * 2000-09-14 2002-03-21 Merck And Co., Inc. Alpha v integrin receptor antagonists
US6509347B2 (en) 2001-06-11 2003-01-21 Merck & Co., Inc. Crystalline forms of an integrin receptor antagonist
SMT201700611T1 (it) 2013-02-07 2018-01-11 Scifluor Life Sciences Inc Antagonisti fluorurati di integrine
US8901144B2 (en) * 2013-02-07 2014-12-02 Scifluor Life Sciences, Llc Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives
WO2016134223A2 (en) * 2015-02-19 2016-08-25 Scifluor Life Sciences, Inc. Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof
EP3273965A4 (en) * 2015-03-26 2018-12-05 Merck Sharp & Dohme Corp. Composition and methods for treating chronic kidney disease

Similar Documents

Publication Publication Date Title
JP2018514568A5 (cg-RX-API-DMAC7.html)
JP2019034943A5 (cg-RX-API-DMAC7.html)
JP2018510139A5 (cg-RX-API-DMAC7.html)
JP2016518437A5 (cg-RX-API-DMAC7.html)
JP2016520618A5 (cg-RX-API-DMAC7.html)
JP2019094345A5 (cg-RX-API-DMAC7.html)
JP2017537940A5 (cg-RX-API-DMAC7.html)
JP2015508103A5 (cg-RX-API-DMAC7.html)
JP2016040288A5 (cg-RX-API-DMAC7.html)
JP2016534063A5 (cg-RX-API-DMAC7.html)
JP2016509591A5 (cg-RX-API-DMAC7.html)
JP2017528503A5 (cg-RX-API-DMAC7.html)
RU2017141561A (ru) Производные тетрагидронафтиридинилпропионовой кислоты и их применение
JP2013544276A5 (cg-RX-API-DMAC7.html)
JP2016512547A5 (cg-RX-API-DMAC7.html)
JP2016503797A5 (cg-RX-API-DMAC7.html)
JP2018537535A5 (cg-RX-API-DMAC7.html)
JP2017505779A5 (cg-RX-API-DMAC7.html)
JP2016522254A5 (cg-RX-API-DMAC7.html)
RU2017116196A (ru) 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1
JP2014500265A5 (cg-RX-API-DMAC7.html)
JP2017517538A5 (cg-RX-API-DMAC7.html)
JP2016531126A5 (cg-RX-API-DMAC7.html)
JP2015521156A5 (cg-RX-API-DMAC7.html)
JP2019520344A5 (cg-RX-API-DMAC7.html)